GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression

Dilan Athauda(The Francis Crick Institute), Sonia Gandhi(The Francis Crick Institute), Maja Mustapić(Institute on Aging), Stephanie Strohbuecker(The Francis Crick Institute), Nirosen Vijiaratnam(Western Health), Judi O’Shaughnessy(MRC Centre for Regenerative Medicine), Thomas Foltynie(National Hospital for Neurology and Neurosurgery), Gurvir S. Virdi(The Francis Crick Institute), James R. Evans(The Francis Crick Institute), Mathew H. Horrocks(MRC Centre for Regenerative Medicine), Mina Ryten(Guy's Hospital), Christina E. Toomey(University College London), Khalida Ismail(Diabetes UK), Aaron Z. Wagen(Great Ormond Street Hospital), Rebecca S. Saleeb(Heriot-Watt University), Giulia Vecchi(Faculty (United Kingdom)), Nigel H. Greig(National Institutes of Health), Dimitrios Kapogiannis(Office of Extramural Research), Craig Leighton(MRC Centre for Regenerative Medicine), Christine Girges(National Hospital for Neurology and Neurosurgery), Anna I. Wernick(The Francis Crick Institute), Melanie J. Davies(NIHR Leicester Biomedical Research Centre), Laura Mahoney‐Sanchez(The Francis Crick Institute), Yazhou Li(National Institute on Aging), Patricia Lopez-Garcia(The Francis Crick Institute), Karishma D’Sa(The Francis Crick Institute), Minee L. Choi(Korea Advanced Institute of Science and Technology), Joanne Lachica(University College London)
bioRxiv (Cold Spring Harbor Laboratory)
February 28, 2024
Cited by 7


Related Papers